Premium
Long‐Acting Diltiazem CD Is Safe and Effective in a Hypertensive Mexican‐American Population
Author(s) -
Herrera Carlos R.,
Lewin Andrew,
Fiddes Robert,
Friedman Jon,
Linn William,
Baker Thomas,
Balanoff Diane,
Beach C. L.
Publication year - 1997
Publication title -
pharmacotherapy: the journal of human pharmacology and drug therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.227
H-Index - 109
eISSN - 1875-9114
pISSN - 0277-0008
DOI - 10.1002/j.1875-9114.1997.tb03089.x
Subject(s) - diltiazem , medicine , population , pharmacology , environmental health , calcium
Study Objective . To evaluate the safety and effectiveness of diltiazem CD for reducing blood pressure in Mexican‐American patients with mild to moderate hypertension. Design . Randomized, double‐blind, placebo‐controlled trial. Setting . Twelve clinical sites in the United States. Patients . Patients with baseline diastolic blood pressures between 95 and 115 mm Hg. Interventions . Patients were treated with an average daily dose of diltiazem CD 246 mg (60 patients) or placebo (58 patients) to achieve a trough diastolic blood pressure below 90 mm Hg. Measurements and Main Results . Diltiazem CD significantly reduced mean diastolic blood pressure compared with placebo, −8.2 versus −4.1 mm Hg, respectively (p=0.0025). Diastolic blood pressure below 90 mm Hg or a reduction of 10 mm Hg or more was achieved by 57% of diltiazem CD versus 28% of placebo recipients. Systolic blood pressure and heart rate were also reduced with diltiazem CD. Adverse events were mild, with similar frequency for diltiazem CD (15%) and placebo (19%). Conclusion . Diltiazem CD is safe and effective in hypertensive Mexican‐Americans, and diastolic blood pressure reductions compare with those in non‐Hispanic white patients.